Radiation Therapy in Treating Patients With Relapsed Prostate Cancer After Surgery

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Swiss Group for Clinical Cancer Research
ClinicalTrials.gov Identifier:
NCT01272050
First received: January 6, 2011
Last updated: April 29, 2014
Last verified: April 2014
  Purpose

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known which radiation therapy regimen is more effective in treating patients with relapsed prostate cancer.

PURPOSE: This randomized phase III trial is studying the side effects of radiation therapy and comparing two radiation therapy regimens in treating patients with relapsed prostate cancer after surgery.


Condition Intervention Phase
Prostate Cancer
Radiation: radiation therapy
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Factorial Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Dose Intensified Salvage Radiotherapy in Biochemically Relapsed Prostate Cancer Without Macroscopic Disease. A Randomized Phase III Trial.

Resource links provided by NLM:


Further study details as provided by Swiss Group for Clinical Cancer Research:

Primary Outcome Measures:
  • Freedom from biochemical progression [ Time Frame: from the day of trial randomization to the day of either first recorded biochemical progression, or death due to clinical progression. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Clinical progression-free survival [ Time Frame: from the day of randomization to the day of the first record of either local or regional recurrence, distant recurrence, start of hormonal treatment, or death due to any cause ] [ Designated as safety issue: No ]
  • Time to hormonal treatment [ Time Frame: time from trial randomization to start of hormonal treatment ] [ Designated as safety issue: No ]
  • Prostate cancer-specific survival [ Time Frame: time from trial randomization to the date of death due to prostate cancer ] [ Designated as safety issue: No ]
  • Overall survival [ Time Frame: time from trial randomization to the date of death from any cause ] [ Designated as safety issue: No ]
  • Acute and late gastrointestinal and genitourinary toxicity according to CTCAE v 4.0 [ Time Frame: occurring during treatment and up to 3 months after completion of treatment. Late toxicity is defined as occurring later than 3 months after end of treatment. ] [ Designated as safety issue: Yes ]
  • Quality of life [ Time Frame: n.a. ] [ Designated as safety issue: No ]

Estimated Enrollment: 350
Study Start Date: January 2011
Estimated Study Completion Date: December 2025
Estimated Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Arm A: 64 Gy
Arm A: 64 Gy (32 x 2 Gy) without hormonal treatment
Radiation: radiation therapy

RT in the standard arm A will be administered to a total dose of 64 Gy in 32 fractions of 2 Gy over 6.4 weeks. RT in the experimental arm B will be administered to a total dose of 70 Gy in 35 fractions of 2 Gy over 7 weeks.

Megavoltage equipments with nominal photon energies ≥ 6 MV are required. Rotational techniques such as Tomotherapy®, Rapidarc®, intensity-modulated arc technique (IMAT) and volumetric-modulated arc therapy (VMAT) will also be eligible. The patient will be treated in an isocentric setting and all fields will be applied for 5 days per week for the total RT duration.

Active Comparator: Arm B: 70 Gy
Arm B: 70 Gy (35 x 2 Gy) without hormonal treatment
Radiation: radiation therapy

RT in the standard arm A will be administered to a total dose of 64 Gy in 32 fractions of 2 Gy over 6.4 weeks. RT in the experimental arm B will be administered to a total dose of 70 Gy in 35 fractions of 2 Gy over 7 weeks.

Megavoltage equipments with nominal photon energies ≥ 6 MV are required. Rotational techniques such as Tomotherapy®, Rapidarc®, intensity-modulated arc technique (IMAT) and volumetric-modulated arc therapy (VMAT) will also be eligible. The patient will be treated in an isocentric setting and all fields will be applied for 5 days per week for the total RT duration.


Detailed Description:

OBJECTIVES:

  • To determine the tumor control in patients with biochemically relapsed prostate cancer without macroscopic disease treated with dose-intensive salvage radiotherapy.
  • To determine the toxicity in these patients.
  • To determine the quality of life of these patients.

OUTLINE: This is a multicenter study. Patients are stratified according to Gleason score (≥ 8 vs 7 vs ≤ 6), pathological tumor classification (pT3b vs others), lymphadenectomy performed (yes [pN0] vs no [cN0]), persistent PSA after prostatectomy (detectable [≥ 0.1 ng/mL] vs undetectable [< 0.1 ng/mL]), PSA at randomization (> 0.5 ng/mL vs ≤ 0.5 ng/mL), participating center, and radiotherapy technique (3-dimensional conformal radiation therapy [3D-CRT] vs intensity-modulated radiation therapy [IMRT]/rotational techniques). Patient are randomized to 1 of 2 treatment arms.

  • Arm A: Beginning at least 12 weeks after surgery, patients undergo radiotherapy* once a day, 5 days a week, for 6.4 weeks for a total dose of 64 Gy (in 32 fractions of 2 Gy over 6.4 weeks).
  • Arm B: Patients undergo radiotherapy* once a day, 5 days a week, for 7 weeks for a total dose of 70 Gy (in 35 fractions of 2 Gy over 7 weeks).

NOTE: *3-dimensional conformal radiation therapy, rotational techniques such as Tomotherapy®, Rapidarc®, or intensity-modulated arc technique and volumetric-modulated arc therapy are all eligible.

Patients complete quality-of-life questionnaires at baseline and at 3, 12, 24, 36, 48, and 60 months after completing study therapy.

After completion of study treatment, patients are followed every 6 months for 3 years and then every 12 months for up to 10 years.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Diagnosis of adenocarcinoma of the prostate

    • Lymph node negative disease

      • Stage pT2a-3b; R0-1; pN0 or cN0
  • Undergone a radical prostatectomy ≥ 12 weeks prior to randomization
  • PSA progression after prostatectomy defined as two consecutive rises with the second rising value > 0.1 ng/mL OR three consecutive rises (the first value must be measured 4 weeks after radical prostatectomy)
  • PSA ≤ 2 ng/mL at randomization

    • No persistent PSA > 0.4 ng/mL, 4-20 weeks after radical prostatectomy
  • No palpable prostatic fossa mass suggestive of recurrence, unless an ultrasound-guided biopsy is non-malignant
  • No pre-salvage radiotherapy pelvic lymph node enlargement > 1 cm in short axis diameter of the abdomen and pelvis (cN1) (unless the enlarged lymph node is sampled and negative)
  • No evidence of macroscopic local recurrence or metastatic disease on pre-salvage radiotherapy MRI (with IV contrast) or multislice computed tomography (with IV and oral contrast) of the abdomen and pelvis assessed within 16 weeks prior to randomization
  • No presence or history of bone metastases (bone scan must be performed in case of clinical suspicion [e.g., bone pain])
  • Gleason score must be available

PATIENT CHARACTERISTICS:

  • WHO performance status 0-1
  • Fertile patients must use effective contraception during and for 6 months after completion of study therapy
  • Compliant and geographically proximal to allow for proper staging and follow-up
  • No prior invasive malignancy, except non-melanomatous skin cancer or other malignancies with a documented disease-free survival of ≥ 5 years
  • No bilateral hip prosthesis
  • No severe or active co-morbidity likely to impact on the advisability of dose-intensive salvage radiotherapy, including any of the following:

    • History of inflammatory bowel disease
    • Acute bacterial or fungal infection requiring intravenous antibiotics at the time of randomization
    • Unstable angina and/or congestive heart failure requiring hospitalization within the past 6 months
    • Transmural myocardial infarction within the past 6 months
    • Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of randomization
  • No psychiatric disorder precluding understanding of information on trial-related topics, giving informed consent, or filling out quality-of-life questionnaires

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  • No prior pelvic radiotherapy
  • No hormonal treatment or bilateral orchiectomy prior to or following prostatectomy
  • At least 4 weeks since prior and no concurrent use of products known to affect PSA levels (e.g., PC Calm, PC Plus, PC SPES, finasteride, or fluconazole)
  • At least 30 days since prior treatment in another clinical trial
  • No other concurrent anticancer treatments, including luteinizing hormone-releasing hormone (LHRH) analogues, antiandrogens, orchiectomy, or chemotherapy
  • No other concurrent investigational or experimental treatments or drugs

INCLUSION CRITERIA

  • Patient must give written informed consent before randomization.
  • Lymph node negative adenocarcinoma of the prostate treated with radical prostatectomy at least 12 weeks before randomization. Tumor stage pT2a-3b, R0-1, pN0 or cN0 according to the UICC TNM 2009 (see Appendix 1), Gleason score available.
  • PSA progression after prostatectomy defined as two consecutive rises with the final PSA > 0.1 ng/mL or three consecutive rises. The first value must be measured earliest 4 weeks after radical prostatectomy.
  • PSA at randomization ≤ 2 ng/mL.
  • WHO performance status 0-1 at randomization.
  • Age at randomization between 18 and 75 years.
  • Baseline QoL questionnaire (QLQ) has been completed.
  • Patient agrees not to father a child during salvage RT and during 6 months thereafter.
  • Patient compliance and geographic proximity allow proper staging and follow-up.
  • The responsible pathologist has agreed to provide sample material for central pathological review (see Section 16) and tissue banking (only if patient gave informed consent) within the specified timelines.

EXCLUSION CRITERIA

  • Persistent PSA 4-20 weeks after radical prostatectomy > 0.4 ng/mL
  • Palpable prostatic fossa mass suggestive of recurrence, unless an ultrasound guided biopsy is non-malignant.
  • Pre-salvage RT pelvic lymph node enlargement > 1 cm in short axis diameter of the abdomen and pelvis (cN1), unless the enlarged lymph node is sampled and negative, and/or evidence of macroscopic local recurrence or metastatic disease on pre-salvage RT MRI (magnetic resonance imaging; with i.v. contrast) or multislice computed tomography (CT; with i.v. and oral contrast) of the abdomen and pelvis assessed within 16 weeks prior to randomization.
  • Presence or history of bone metastases. Bone scan must be performed in case of clinical suspicion (e.g. bone pain).
  • Prior invasive malignancy, except non-melanomatous skin cancer or other malignancies with a documented disease-free survival for a minimum of 5 years.
  • Hormonal treatment or bilateral orchiectomy prior to or following prostatectomy.
  • Bilateral hip prosthesis.
  • Prior pelvic radiotherapy.
  • The use of products known to affect PSA levels within 4 weeks prior to start of trial treatment (e.g. PC Calm, PC Plus, PC SPES, finasteride, fluconazole).
  • Severe or active co-morbidity likely to impact on the advisability of dose intensified salvage RT.
  • Psychiatric disorder precluding understanding of information on trial related topics, giving informed consent or filling out QoL questionnaires.
  • Concurrent treatment with other experimental drugs or other anti-cancer therapy, treatment in a clinical trial within 30 days prior to trial entry.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01272050

Locations
Belgium
Ziekenhuis Netwerk Antwerpen Middelheim
Antwerpen, Belgium, 2020
Ghent University Hospital
Ghent, Belgium, 9000
St. Lukas Hospital Ghent
Ghent, Belgium, 9000
Germany
Universitaetsklinikum Aachen, Klinik für Strahlentherapie
Aachen, Germany, 52074
Charite University Hospital - Campus Virchow Klinikum
Berlin, Germany, 13353
University Hospital and Medical Faculty Technical University of Dresden
Dresden, Germany, D-01307
Universitaetsklinikum Essen, Klinik für Strahlentherapie
Essen, Germany, 45147
Universitätsklinikum Saarland
Homburg/Saar, Germany, 66421
Klinikum der LMU Muenchen
Munich, Germany, D-81377
Technische Universitaet Muenchen
Munich, Germany, D-81675
Klinikum der Universitaet Regensburg
Regensburg, Germany, 93051
Klinik und Poliklinik fuer Strahlentherapie - Universitaetsklinikum Rostock
Rostock, Germany, 18059
Universitaet Tuebingen
Tuebingen, Germany, 72076
Klinik fuer Strahlentherapie Universitaet Wuerzburg
Wuerzburg, Germany, 97080
Switzerland
Kantonsspital Aarau
Aarau, Switzerland, 5001
Universitaetsspital-Basel
Basel, Switzerland, CH-4031
Istituto Oncologico della Svizzera Italiana - Ospedale Regionale Bellinzona e Valli
Bellinzona, Switzerland, 6500
Inselspital Bern
Bern, Switzerland, 3010
Radio-Onkologiezentrum Biel-Seeland-Berner Jura AG
Biel, Switzerland, 2503
Kantonsspital Graubuenden
Chur, Switzerland, 7000
Kantonsspital Luzern
Luzern, Switzerland, 6000
Kantonsspital Muensterlingen
Muensterlingen, Switzerland, 8596
Hopital de Sion
Sion, Switzerland, 1951
Kantonsspital - St. Gallen
St. Gallen, Switzerland, 9007
Radio-Onkologie Berner Oberland AG 

Thun, Switzerland, 3600
UniversitaetsSpital Zuerich
Zurich, Switzerland, 8091
City Hospital Triemli
Zurich, Switzerland, 8063
Klinik Hirslanden
Zurich, Switzerland, 8032
Sponsors and Collaborators
Swiss Group for Clinical Cancer Research
Investigators
Study Chair: Pirus Ghadjar, MD Charité Berlin
Study Chair: Daniel M. Aebersold, Prof. Bern University Hospital
Study Chair: George N. Thalmann, Prof. Bern University Hospital
Study Chair: Daniel Zwahlen, PD Dr. Kantonsspital Graubünden
  More Information

No publications provided

Responsible Party: Swiss Group for Clinical Cancer Research
ClinicalTrials.gov Identifier: NCT01272050     History of Changes
Other Study ID Numbers: SAKK 09/10, SWS-SAKK-09/10, EU-21088, CDR0000691926
Study First Received: January 6, 2011
Last Updated: April 29, 2014
Health Authority: Switzerland: Ethikkommission

Keywords provided by Swiss Group for Clinical Cancer Research:
adenocarcinoma of the prostate
recurrent prostate cancer
stage IIA prostate cancer
stage IIB prostate cancer
stage III prostate cancer

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms
Neoplasms by Site
Prostatic Diseases
Urogenital Neoplasms

ClinicalTrials.gov processed this record on October 21, 2014